Tolerability of Iron Therapy in Women With AUB
Study Details
Study Description
Brief Summary
Telephone surveys of female patients using liposomally-bound iron and traditional iron sulphate preparations for the management of iron deficiency anemia to determine gastrointestinal tolerability.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
- Rationale and Background:
Abnormal uterine bleeding (AUB) affects women worldwide. In high income countries, heavy menstrual bleeding (a subset of AUB) is the most common cause of iron deficiency (ID) and iron deficiency anemia (IDA). Although estimates vary, it appears that 20-30% of IDA is a result of heavy menstrual bleeding. Oral iron replacement is a common treatment modality among patients diagnosed with IDA. However, traditional oral iron preparations commonly result in significant gastrointestinal side effects due to the metabolism of the complex that the iron is bound to. Gastrointestinal side effects related to iron therapy, including: metallic taste, nausea, flatulence, constipation, diarrhea, epigastric distress, vomiting, and melena. Therefore, liposomally bound iron is thought to provide a better side effect profile due to avoiding these traditional complexes. In theory, this will lead to higher rates of compliance and treatment efficacy if patients are not experiencing these side effects. Although we have limited data on the efficacy of this iron preparation, the literature suggests that other types of liposomally bound medications have similar efficacy as traditional preparations. Therefore, we believe that liposomally bound iron will provide an effective and well tolerated option for women suffering from IDA secondary to AUB.
- Research Question and Objectives:
How does a novel liposomally-bound iron therapy compare to ferrous sulphate in women with anemia secondary to abnormal uterine bleeding? 2a. Determine if it has less gastrointestinal side effects than ferrous sulphate 2b. Determine if it has similar efficacy to ferrous sulphate in correcting anemia secondary to abnormal uterine bleeding
- Methods:
Pre-menopausal women, diagnosed with anemia secondary to abnormal uterine bleeding Recruitment via physician offices of gynecologists in Calgary, AB Two treatment arms, n=10 per arm Ferrous sulphate compared to treatment arm (liposomally bound iron) Baseline hemoglobin prior to iron therapy initiation Pre-op hemoglobin to compare efficacy of iron therapy Phone interview with patients using standardized, validated questionnaire to collect information regarding gastrointestinal side effects
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Ferrous Sulphate Women age 18-50 yo that have been diagnosed with iron deficiency anemia secondary to abnormal uterine bleeding using Ferrous Sulphate for iron replacement |
Dietary Supplement: Liposomally-bound Iron
Ferric pyrophosphate microencapsulated in liposomal form is an over the counter natural health product approved by Health Canada and commonly used for iron replacement. If this product is prescribed as part of usual management of iron deficiency and patients consent to participation they will be contacted by telephone survey of gastrointestinal tolerability.
|
| Liposomally-bound Iron Women age 18-50 yo that have been diagnosed with iron deficiency anemia secondary to abnormal uterine bleeding using Liposomally-bound Iron for iron replacement |
Dietary Supplement: Liposomally-bound Iron
Ferric pyrophosphate microencapsulated in liposomal form is an over the counter natural health product approved by Health Canada and commonly used for iron replacement. If this product is prescribed as part of usual management of iron deficiency and patients consent to participation they will be contacted by telephone survey of gastrointestinal tolerability.
|
Outcome Measures
Primary Outcome Measures
- Subjective tolerability of oral administration [8 weeks]
Survey of gastrointestinal reactions to iron replacement
Secondary Outcome Measures
- Hemoglobin [8 weeks]
Relative change of hemoglobin
- Hematocrit [8 weeks]
Relative change of hematocrit
- Ferritin [8 weeks]
Relative change of ferritin
Eligibility Criteria
Criteria
Inclusion Criteria:
- Diagnosed with iron deficiency secondary to abnormal uterine bleeding
Exclusion Criteria:
- Postmenopausal, premenarchal and pregnant women are excluded, as they do not have regular uterine bleeding associated with menses.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- University of Calgary
Investigators
- Principal Investigator: Chandrew Rajakumar, M.D., University of Calgary
Study Documents (Full-Text)
None provided.More Information
Publications
- REB20-1546